baxdrostat
baxdrostat: sourced relationships with 1 company · 7 clinical trials tracked.
baxdrostat evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could baxdrostat → CINC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| CinCor Pharma, Inc. (CINC) | — |
Clinical Trial Registry Records (7)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics
Primary endpoint: Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Baxdrostat on Ventricular Remodeling
Primary endpoint: Left Ventricular Mass indexed to baseline body surface area (LVMi)
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism
Primary endpoint: Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8
A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death
Primary endpoint: To determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of an HF event or CV death
A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Primary endpoint: Change from baseline in seated SBP at Week 12
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Primary endpoint: Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Primary endpoint: Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat
Frequently asked questions
Which companies have sourced relationships with baxdrostat?
baxdrostat has dated SEC/FDA relationship records for CinCor Pharma, Inc..
How many clinical trials involve baxdrostat?
BioSniper tracks 7 clinical trials involving baxdrostat.